Acellular Regeneration 

Through a proprietary process, viable cells and cellular elements that are capable of triggering an immunogenic response are removed from donated human dermal tissue, leaving behind a collagen elastin matrix. Upon transplantation, the body’s own cells infiltrate and repopulate this three-dimensional scaffold to begin the revascularization and remodeling processes. Unlike xenografts (animal-derived), acellular allograft matrices minimize the risk of inflammation³ and/or host rejection⁴ during the graft incorporation process, since the tissue is a human-derived scaffold.

DermaTrue™ Decellularization Process

AlloMend^® ADM is created using AlloSource’s proprietary DermaTrue™ Decellularization Process to remove cellular debris (including DNA, RNA, proteins and antigens), without the use of harsh detergents or enzymes which can leave residuals in the tissue. The dermal tissue is rendered acellular, contributing to a low immunologic response¹, while retaining growth factors and maintaining the morphological collagen structure.⁵ AlloMend has been shown to incorporate into the surgical site and demonstrate blood vessel infiltration.¹

High Tensile and Suture Retention Strength

AlloMend ADM exceeds the tensile strength of leading acellular dermal matrices for more assurance in the surgical repair of integumental tissue.⁶  Ultimate tensile strength is a standard testing methodology to measure the force needed to stretch and break a biomaterial. AlloMend ADM also demonstrates high suture retention strength, often exceeding the inherent strength of the sutures themselves. AlloMend UltraThick ADM (from 3.0-4.0 mm), can be expected to have a suture pullout strength of between 161 and 270 N. This helps ensure secure placement during the most demanding soft tissue repair.⁷

AlloMend^® Duo ADM Dual-sided Reticular Dermal Matrix for Non-Directional Implantation

AlloMend^® Duo ADM is a non-directional allograft cut from the deep-reticular dermal tissue. Both sides of the allograft have nearly equivalent tissue structures for ease of use and for increased confidence during implantation.

‍

‍

_REFERENCES

_{1. Stilwell R, Delaney R. The biomechanics of AlloMend acellular dermal matrix: Biocompatibility study. AlloSource White Paper.2016;00088-LIT[001].}

_{2. Blume, L., Sakthivel, R. The biomechanical properties of meshed AlloMend acellular dermal AlloSource White Paper matrix: Fluid egress and surface area, 2019; 00149-LIT [001]}

_{3. Richters C, et al. Development of a dermal matrix from glycerol preserved allogenic skin. Cell and Tissue Banking. 2008; 9(4): 309-15.}

_{4. Michael TE. Xenograft risks: What you and your patients need to know. American Academy of Orthopaedic Surgeons. www.aaos.org/news/aaosnow/jun09/research3.asp.}

_{5. Delaney R, Stilwell R. The biologic properties of AlloMend acellular dermal matrix: Growth factor study. AlloSource White Paper. 2016; M8S0115.001.}

_{6. Stevens PJ, et al. The biomechanics of AlloMend acellular dermal matrix: Ultimate tensile strength. AlloSource White Paper. 2020; 00048-LIT [002].}

_{7. Stilwell R, et al. The biomechanics of AlloMend acellular dermal matrix: Suture retention strength. AlloSource White Paper. 2020; 00078-LIT [002].}